OptimizeRx (OPRX) News Today $10.05 +0.41 (+4.25%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$10.04 -0.01 (-0.06%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period JPMorgan Chase & Co. Buys 52,169 Shares of OptimizeRx Co. (NASDAQ:OPRX)JPMorgan Chase & Co. boosted its stake in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 670.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 59,952 shares of the company's stock after purchasing an additional 52,169 shares during the period.May 5 at 3:06 AM | marketbeat.comManatuck Hill Partners LLC Takes Position in OptimizeRx Co. (NASDAQ:OPRX)Manatuck Hill Partners LLC bought a new stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 100,000 shares of the company's stock, valued at approximately $486,00May 4 at 6:53 AM | marketbeat.comMarshall Wace LLP Invests $653,000 in OptimizeRx Co. (NASDAQ:OPRX)Marshall Wace LLP bought a new position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 134,446 shares of the company's stock, valued at approximately $653,000. Marshall Wace LLP owned 0.73% of OptimizeRx at theMay 4 at 3:44 AM | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Shares Acquired by Connors Investor Services Inc.Connors Investor Services Inc. raised its position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 170.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 59,000 shares of the company's stock after acquiring an additiMay 2 at 7:33 AM | marketbeat.comOptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) ReportMay 1, 2025 | globenewswire.com36,674 Shares in OptimizeRx Co. (NASDAQ:OPRX) Purchased by XTX Topco LtdXTX Topco Ltd acquired a new stake in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 36,674 shares of the company's stock, valuedApril 30, 2025 | marketbeat.comWalleye Capital LLC Takes Position in OptimizeRx Co. (NASDAQ:OPRX)Walleye Capital LLC acquired a new stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 138,575 shares of the company's stock, valued at approximately $673,000. Walleye CapApril 25, 2025 | marketbeat.comOptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ETApril 23, 2025 | globenewswire.comLake Street Sticks to Their Buy Rating for OptimizeRx (OPRX)April 22, 2025 | markets.businessinsider.comOptimizeRx Corporation Announces Plan for Additional Board of Directors RefreshmentApril 18, 2025 | globenewswire.comKennedy Capital Management LLC Acquires 217,676 Shares of OptimizeRx Co. (NASDAQ:OPRX)Kennedy Capital Management LLC increased its holdings in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 57.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 594,000 shares of the company's stock after acquiring an addApril 16, 2025 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) have received an average rating of "Moderate Buy" from the nine analysts that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation andApril 15, 2025 | marketbeat.comWhetstone Capital Advisors LLC Purchases New Shares in OptimizeRx Co. (NASDAQ:OPRX)Whetstone Capital Advisors LLC bought a new position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,350,423 shares of the company's stock, valued at approximately $6,563,000. OptimizeRx comprisApril 13, 2025 | marketbeat.comLake Street Remains a Buy on OptimizeRx (OPRX)April 10, 2025 | markets.businessinsider.comShort Interest in OptimizeRx Co. (NASDAQ:OPRX) Grows By 22.0%OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,720,000 shares, a growth of 22.0% from the February 28th total of 1,410,000 shares. Currently, 11.1% of the shares of the stock are short sold. Based on an average trading volume of 502,300 shares, the short-interest ratio is currently 3.4 days.April 4, 2025 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Stake Reduced by Blair William & Co. ILBlair William & Co. IL trimmed its stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 11.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 601,383 shares of the company's stock after selling 75,711 shares during the quarter. Blair William & Co. IApril 2, 2025 | marketbeat.comOptimizeRx Corporation (NASDAQ:OPRX) is favoured by institutional owners who hold 59% of the companyMarch 30, 2025 | finance.yahoo.comOptimizeRx files $75M mixed securities shelfMarch 29, 2025 | markets.businessinsider.comOptimizeRx (OPRX) Gets a Buy from Lake StreetMarch 21, 2025 | markets.businessinsider.comInsider Buying: OptimizeRx Co. (NASDAQ:OPRX) Director Purchases 321,408 Shares of StockOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) Director James Paul Lang bought 321,408 shares of the stock in a transaction on Friday, March 14th. The shares were acquired at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the purchase, the director now owns 389,452 shares in the company, valued at approximately $2,959,835.20. This represents a 472.35 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.March 20, 2025 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Director James Paul Lang Acquires 321,408 SharesMarch 20, 2025 | insidertrades.comRoyce & Associates LP Takes $5.20 Million Position in OptimizeRx Co. (NASDAQ:OPRX)Royce & Associates LP acquired a new position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,069,560 shares of the company's stock, valued at approximately $5,198,000. RoMarch 20, 2025 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine analysts that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and onMarch 19, 2025 | marketbeat.comOptimizeRx management to meet with Lake StreetMarch 19, 2025 | markets.businessinsider.comOptimizeRx (OPRX) to Release Quarterly Earnings on WednesdayOptimizeRx (NASDAQ:OPRX) will be releasing earnings after the market closes on Wednesday, March 26, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=671031)March 19, 2025 | marketbeat.comWhy OptimizeRx Corp. (OPRX) Soared Last Week?March 17, 2025 | msn.comResearch Analysts Issue Forecasts for OptimizeRx Q1 EarningsOptimizeRx Co. (NASDAQ:OPRX - Free Report) - Analysts at Roth Capital issued their Q1 2026 EPS estimates for shares of OptimizeRx in a report issued on Wednesday, March 12th. Roth Capital analyst R. Baldry anticipates that the company will post earnings of ($0.19) per share for the quarter. The cMarch 17, 2025 | marketbeat.comWhat is B. Riley's Estimate for OptimizeRx Q1 Earnings?OptimizeRx Co. (NASDAQ:OPRX - Free Report) - Research analysts at B. Riley issued their Q1 2025 EPS estimates for OptimizeRx in a research note issued to investors on Wednesday, March 12th. B. Riley analyst A. Schock forecasts that the company will earn ($0.34) per share for the quarter. B. RileyMarch 17, 2025 | marketbeat.comOptimizeRx (NASDAQ:OPRX) Upgraded at B. RileyB. Riley raised OptimizeRx to a "strong-buy" rating in a research note on Wednesday.March 15, 2025 | marketbeat.comOptimizeRx Corporation (NASDAQ:OPRX) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | msn.comOptimizeRx (NASDAQ:OPRX) Issues Quarterly Earnings ResultsOptimizeRx (NASDAQ:OPRX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.25 by ($0.11). OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%.March 13, 2025 | marketbeat.comOptimizeRx Q4 results ‘at odds with muted’ outlook, says Roth MKMMarch 12, 2025 | markets.businessinsider.comOptimizeRx Appoints Steve Silvestro As CEOMarch 12, 2025 | nasdaq.comOptimizeRx reports Q4 EPS 30c, consensus 27cMarch 12, 2025 | markets.businessinsider.comOptimizeRx Corporation (OPRX) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | seekingalpha.comOptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 MillionMarch 12, 2025 | benzinga.comOptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial ResultsMarch 12, 2025 | globenewswire.comOptimizeRx confirems receipt of notice of director nominationsMarch 11, 2025 | markets.businessinsider.comOptimizeRx Corporation Confirms Receipt of Notice of Director NominationsMarch 11, 2025 | globenewswire.comOptimizeRx appoints Silvestro as CEOMarch 10, 2025 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on OptimizeRx (OPRX)March 10, 2025 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on OptimizeRx (OPRX)March 10, 2025 | markets.businessinsider.comOptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive OfficerMarch 10, 2025 | globenewswire.comWhat Does OptimizeRx Corporation's (NASDAQ:OPRX) Share Price Indicate?March 5, 2025 | finance.yahoo.comOptimizeRx (OPRX) Projected to Post Earnings on WednesdayOptimizeRx (NASDAQ:OPRX) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=671031)March 5, 2025 | marketbeat.comOptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ETFebruary 27, 2025 | globenewswire.comOptimizeRx Co. (NASDAQ:OPRX) Receives Consensus Rating of "Moderate Buy" from AnalystsOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine brokerages that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. TheFebruary 22, 2025 | marketbeat.comOne OptimizeRx Insider Raised Their Stake In The Previous YearFebruary 12, 2025 | uk.finance.yahoo.comOptimizeRx's (OPRX) "Market Outperform" Rating Reaffirmed at JMP SecuritiesJMP Securities reiterated a "market outperform" rating and set a $8.00 price objective on shares of OptimizeRx in a report on Thursday.February 6, 2025 | marketbeat.comOptimizeRX edges higher as holder pushes firm to explore a saleFebruary 6, 2025 | msn.com Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Media Mentions By Week OPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPRX News Sentiment▼1.450.77▲Average Computer and Technology News Sentiment OPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPRX Articles This Week▼62▲OPRX Articles Average Week Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Thryv News Accolade News Priority Technology News Willdan Group News MediaAlpha News Enviri News Montrose Environmental Group News DoubleDown Interactive News The RMR Group News Advantage Solutions News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPRX) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
